Welcome to the Oncomine Blog
Genomic Profiling from Initial Assessment to Detection of Measurable Residual Disease (MRD): How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms
10/27/2022 |
Hemato-oncology
In his recent webinar, Dr. Bevan Tandon makes a compelling case for how next-generation sequencing (NGS) can deliver rapid insights for myeloid...
-
Comprehensive Biomarker Testing Reveals RET Alteration to Change Course of NSCLC Patient’s Treatment Options and Survival Outcome
It’s been a tough road for Melissa Crouse, sometimes almost deadly. She had a lobe of her left lung ... -
Building a Case for In-House Next Generation Sequencing
Diagnostics lab team demonstrates how insourcing NGS makes sound financial sense and helps deliver c... -
Q2 Solutions Eyes Genexus System as its Game-Changing Solution for Global Clinical Trial Services
When it comes to supporting clinical trials, having a global footprint is simply not enough for cont... -
Shifting the Paradigm: Broader Patient Access to Personalized Oncology Treatments Hinges on In-House Comprehensive Genomic Testing
We are living in an unprecedented time in the collective fight against cancer, where recent developm... -
The Importance of Detecting the Most Fusions Across the Most Patients
In recent years, we’ve seen an increasing number of new therapies emerge that target gene fusions in...